Telomir Pharmaceuticals (NASDAQ: TELO) announced new research findings from The Ohio State University College of Veterinary Medicine showing that its lead compound, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway leveraging naturally occurring canine osteosarcoma as a model for human disease.
The implications of this announcement are significant for Telomir's pipeline and for the broader field of osteosarcoma research. Osteosarcoma is a rare but aggressive bone cancer that predominantly affects children and adolescents, and treatment options have remained largely unchanged for decades. The ability of Telomir-Zn to inhibit growth in both human and canine osteosarcoma cells at similar concentrations suggests a conserved mechanism that could be exploited therapeutically. Canine osteosarcoma is a naturally occurring disease that closely resembles the human condition in terms of genetics, biology, and clinical behavior, making it a valuable translational model. If Telomir-Zn proves effective in dogs, it could accelerate development for human use, potentially leading to new treatments for a patient population with high unmet need.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. The company's immediate focus, however, remains its triple-negative breast cancer (TNBC) program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic TNBC. Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation, targeting epigenetic and metabolic pathways implicated in cancer.
The osteosarcoma findings add to the growing body of evidence supporting Telomir-Zn's potential across multiple cancer types. While the TNBC program is further along in development, the osteosarcoma data could provide a second avenue for clinical exploration, particularly if the in vivo studies confirm the in vitro results. For investors, this announcement highlights the versatility of Telomir's platform and the potential for additional value creation beyond the lead indication. The company's strategy of using canine osteosarcoma as a translational bridge is innovative and could reduce the time and cost typically associated with developing new oncology drugs.
To view the full press release, visit https://nnw.fm/laeGH. For more information about Telomir Pharmaceuticals, visit their newsroom at https://nnw.fm/TELO. Additional details about NetworkNewsWire can be found at https://www.NetworkNewsWire.com.
